Strong Data For CARsgen’s CAR-T In Late-Line Gastric Cancer
Survival Benefits Demonstrated
CARsgen Therapeutics’ satricabtagene autoleucel is world’s first CAR-T cell therapy candidate to deliver positive clinical results in solid tumors. • Source: Shutterstock 
